CryoLife, Inc. (CRY) Announces Quarterly Earnings Results

CryoLife, Inc. (NYSE:CRY) issued its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02, Bloomberg Earnings reports. The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the business posted $0.13 earnings per share. CryoLife updated its FY17 guidance to $40-0.43 EPS.

CryoLife (CRY) opened at 18.40 on Friday. CryoLife has a one year low of $14.03 and a one year high of $20.30. The company has a market capitalization of $615.41 million, a PE ratio of 55.76 and a beta of 0.97. The stock’s 50 day moving average is $19.30 and its 200 day moving average is $17.96.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/08/13/cryolife-inc-cry-releases-quarterly-earnings-results-beats-estimates-by-0-02-eps-updated-updated.html.

Several equities research analysts have issued reports on the stock. BidaskClub downgraded shares of CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research downgraded shares of CryoLife from a “buy” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Northland Securities restated a “buy” rating and set a $23.50 price objective on shares of CryoLife in a research report on Friday, April 28th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $22.00.

In related news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now directly owns 112,282 shares in the company, valued at approximately $2,245,640. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in CRY. B. Riley Financial Inc. acquired a new stake in shares of CryoLife during the second quarter worth approximately $579,000. Dimensional Fund Advisors LP boosted its stake in shares of CryoLife by 6.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after buying an additional 110,973 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of CryoLife by 70.4% in the second quarter. Parametric Portfolio Associates LLC now owns 127,230 shares of the medical equipment provider’s stock worth $2,538,000 after buying an additional 52,584 shares during the last quarter. Connors Investor Services Inc. boosted its stake in shares of CryoLife by 0.9% in the second quarter. Connors Investor Services Inc. now owns 108,907 shares of the medical equipment provider’s stock worth $2,173,000 after buying an additional 932 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of CryoLife by 6.6% in the second quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock worth $33,090,000 after buying an additional 102,540 shares during the last quarter. Institutional investors own 68.13% of the company’s stock.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply